Beam Therapeutics selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg

Reuters03-25 19:03

Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg

Beam Therapeutics announced updated safety and efficacy data from an ongoing Phase 1/2, open-label BEAM-302 trial in alpha-1 antitrypsin deficiency (AATD), with results already presented in the release.
In Part A, the steady-state circulating total AAT mean was 16.1 µM in the 60 mg cohort and 14.4 µM in the 75 mg cohort.
Corrected M-AAT comprised 94% of total AAT in the 60 mg cohort, while mutant Z-AAT reduction reached 84% at steady state.
Safety across 26 single-dose patients was described as well-tolerated up to 75 mg, with no serious AEs and no dose-limiting toxicities as of the February 10, 2026 data cutoff.
The company selected 60 mg as the optimal biological dose and said a global pivotal cohort is expected to initiate in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603250700PRIMZONEFULLFEED9678073) on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622027012?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622027012","market":"us","top_or_hot":-1,"title":"Beam Therapeutics selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Beam Therapeutics announced updated safety and efficacy data from an ongoing Phase 1/2, open-label BEAM-302 trial in alpha-1 antitrypsin deficiency (AATD), with results already presented in the release.\n        </li>\n<li>\n          In Part A, the steady-state circulating total AAT mean was 16.1 µM in the 60 mg cohort and 14.4 µM in the 75 mg cohort.\n        </li>\n<li>\n          Corrected M-AAT comprised 94% of total AAT in the 60 mg cohort, while mutant Z-AAT reduction reached 84% at steady state.\n        </li>\n<li>\n          Safety across 26 single-dose patients was described as well-tolerated up to 75 mg, with no serious AEs and no dose-limiting toxicities as of the February 10, 2026 data cutoff.\n        </li>\n<li>\n          The company selected 60 mg as the optimal biological dose and said a global pivotal cohort is expected to initiate in the second half of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603250700PRIMZONEFULLFEED9678073) on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Beam Therapeutics announced updated safety and efficacy data from an ongoing Phase 1/2, open-label BEAM-302 trial in alpha-1 antitrypsin deficiency (AATD), with results already presented in the release.\n        </li>\n<li>\n          In Part A, the steady-state circulating total AAT mean was 16.1 µM in the 60 mg cohort and 14.4 µM in the 75 mg cohort.\n        </li>\n<li>\n          Corrected M-AAT comprised 94% of total AAT in the 60 mg cohort, while mutant Z-AAT reduction reached 84% at steady state.\n        </li>\n<li>\n          Safety across 26 single-dose patients was described as well-tolerated up to 75 mg, with no serious AEs and no dose-limiting toxicities as of the February 10, 2026 data cutoff.\n        </li>\n<li>\n          The company selected 60 mg as the optimal biological dose and said a global pivotal cohort is expected to initiate in the second half of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603250700PRIMZONEFULLFEED9678073) on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL7hmx6f:1","article_id":"2622027012","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622027012","pubTimestamp":1774436604,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Beam Therapeutics selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 M at 60 mg. Beam Therapeutics announced updated safety and efficacy data from an ongoing Phase 1/2, open-label BEAM-302 trial in alpha-1 antitrypsin deficiency , with results already presented in the release.In Part A, the steady-state circulating total AAT mean was 16.1 M in the 60 mg cohort and 14.4 M in the 75 mg cohort.Corrected M-AAT comprised 94% of total AAT in the 60 mg cohort, while mutant Z-AAT reduction reached 84% at steady state.Safety across 26 single-dose patients was described as well-tolerated up to 75 mg, with no serious AEs and no dose-limiting toxicities as of the February 10, 2026 data cutoff.The company selected 60 mg as the optimal biological dose and said a global pivotal cohort is expected to initiate in the second half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BEAM":"Beam Therapeutics, Inc.","BK4535":"淡马锡持仓","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU1861558580.USD":"日兴方舟颠覆性创新基金B","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4112":"金融交易所和数据","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4611":"AI医疗","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Beam Therapeutics选择60 mg BEAM-302进行关键开发；1/2期试验60 mg时平均稳态总AAT攀升至16.1µM","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BEAM":0.9},"content_text":"Beam Therapeutics selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg\n    \n\n\n          Beam Therapeutics announced updated safety and efficacy data from an ongoing Phase 1/2, open-label BEAM-302 trial in alpha-1 antitrypsin deficiency (AATD), with results already presented in the release.\n        \n\n          In Part A, the steady-state circulating total AAT mean was 16.1 µM in the 60 mg cohort and 14.4 µM in the 75 mg cohort.\n        \n\n          Corrected M-AAT comprised 94% of total AAT in the 60 mg cohort, while mutant Z-AAT reduction reached 84% at steady state.\n        \n\n          Safety across 26 single-dose patients was described as well-tolerated up to 75 mg, with no serious AEs and no dose-limiting toxicities as of the February 10, 2026 data cutoff.\n        \n\n          The company selected 60 mg as the optimal biological dose and said a global pivotal cohort is expected to initiate in the second half of 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603250700PRIMZONEFULLFEED9678073) on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622027012","isCrawlerRequest":true}